Managed Care - November 2008 - (Page RSV21)

CONTINUING EDUCATION POST-TEST Respiratory Syncytial Virus (RSV): Prevention Strategies and the Appropriate Identification of Vulnerable Populations Please tear out the assessment/evaluation form on page 20. On the answer sheet, place an X through the box of the letter corresponding to the correct response for each question. There is only ONE correct answer to each question. 1. In the United States, how many infants are hospitalized each year because of severe RSV disease? a. 150,000. b. 50,000 c. 126,000. d. 74,000. 2. In the United States, the RSV season always begins in November and ends in March of each year. a. True. b. False. 3. Which of the following is not a risk factor for severe RSV disease in infants: a. A gestational age (GA) of 28 weeks or less. b. Household crowding. c. School-age siblings. d. Malnutrition. 4. A long-term outcome of RSV in infancy may be: a. Chronic lung disease. b. Physician-diagnosed asthma. c. Allergies. 5. Palivizumab is an FDA-approved that is administered to prevent severe RSV disease in infants. a. Monoclonal antibody, intramuscularly, high-risk. b. Monoclonal antibody, orally, all. c. Polyclonal globulin, intravenously, high-risk. 6. Current AAP guidelines recommend that at the start of an RSV season, palivizumab immunoprophylaxis should be considered for children less than 2 years of age with severe chronic lung disease or congenital heart disease, and also for: a. Infants born 32 weeks GA or less. b. All infants younger than 1 year. c. All infants who are not breastfeeding. 7. According to Frogel, for optimal value, RSV immunoprophylaxis should be given the RSV season begins, terminated after the season, with intramuscular injections of palivizumab administered : a. 2 months before; 1 month after; every 45 days. b. 1 month before; 1 month after; every 30 days . c. 1 week before; at the end of the season; every 30 days. 8. According to Frogel, compliance with immunoprophylaxis for high-risk infants can best be maintained by: a. Better coordination between the neonatal intensive care unit and pediatricians and home-based delivery of palivizumab. b. Parent education. c. Better tracking of high-risk infants to determine adherence to immunoprophylaxis. d. All of the above. 9. Among persons 65 years and older, what percent of deaths can be attributed to RSVassociated underlying respiratory and circulatory diagnoses? a. 65 percent. b. 78 percent. c. Less than 50 percent. 10. The most effective treatment for RSV infections in both the upper and lower respiratory tract in adults is: a. Corticosteroid therapy. b. Antibiotic therapy. c. Good hygiene practices. 11. A primary advantage of Humana’s CareHub information technology program is its ability to: a. Identify specific candidates for RSV case management. b. Keep an accurate record of all medical and pharmacy claims. c. Develop clinical guidelines for RSV immunoprophylaxis. 12. In the management of RSV, Scrip World uses prior authorization as a way to: a. Identify specific candidates for RSV case management. b. Keep an accurate record of all medical and pharmacy claims. c. Develop clinical guidelines for RSV immunoprophylaxis. SUPPLEMENT / RSV 21

Table of Contents Feed for the Digital Edition of Managed Care - November 2008

Managed Care - November 2008 Editor’s Memo Contents News and Commentary Legislation & Regulation Letters Medication Management Compensation Monitor Do It Yourself for Less Biomarkers Promise, but Do They Deliver? Oncologists Complain About Drug Payment Consider Blood Pressure Self-Monitoring Q&A: Keep Industry in the Game Formulary Files Plan Watch Tomorrow’s Medicine Outlook Respiratory Syncytial Virus Managed Care Considerations Contents Continuing Education Objectives RSV Disease in the Pediatric Population In the Trenches RSV Infection in the Adult Population Health Plan Medical Director Health Plan Pharmacy Director RSV Issues and Solutions Assessment/Evaluation/Certificate Request Post-Test

Managed Care - November 2008

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.